ALRT Gears Up for Commercialization of Diabetes Management System

ALR Technologies (ALRT)

ALR Technologies Updates Shareholders on Commercial Launch of Diabetes Management System

ALR Technologies Inc. (OTCBB: ALRT) (the “Company”), a health information technology company, is pleased to provide shareholders with an update for its FDA-cleared Health-e-Connect System (“the System”) for remote monitoring and chronic disease management.

In October 2011, Health-e-Connect received 510(k) clearance from the U.S. Food and Drug Administration for remote monitoring of patients in support of effective diabetes management programs. Since the FDA clearance, the System has been undergoing additional internal product review to ensure ALR Technologies and the Health-e-Connect System comply with HIPAA standards as well as all appropriate FDA and Company quality system requirements. ALR Technologies anticipates that this extensive review will be finalized this quarter; completing the Company’s transition to a medical device manufacturer that is required to legally sell the Health-e-Connect System in the United States. This is imperative to ensure the security and efficacy of the patient information provided and to build shareholder value as the Company moves into the revenue stage.

In preparation for commercial roll-out of Health-e-Connect, the ALRT management team has also been actively engaged in establishing potential partnerships with a number of diabetes test supply manufacturers and distributors, insulin manufacturers, and health insurance payers to offer a unique and comprehensive program for the remote monitoring and management of patients with diabetes.

“Our approach is designed to replicate the success of the clinical trial published in Diabetes Care, August 2010 in an official product launch. We have been in meetings with the major stakeholders in the diabetes industry since receiving our clearance to determine how our System can best support and improve diabetes care and we are now forging partnerships for our product launch,” commented Sidney Chan, Chief Executive Officer at ALR Technologies. “We have formulated a unique business model which, if successfully introduced, will facilitate ALR Technologies emerging as the dominant player in diabetes management. Given the parties involved and the proprietary nature of the business model, there is a high degree of sensitivity with regards to timing and disclosure. The feedback we’ve received to date has been tremendous and shows that Health-e-Connect is drawing strong interest. We anticipate a successful official product launch in the near term.”

About ALR Technologies Inc.
ALRT Health-e-Connect System (“System”) is the principal product of the Company. HeC is a web based patient management platform for medical professionals to improve compliance and adherence of care plans of patients in their homes. The System is programmed to assist healthcare providers caring for diabetes patients. The platform will be expanded to cover patients with other chronic diseases. The System is not available for sale in the US pending product release. More information on ALR Technologies and its products can be found at

This release contains certain “forward-looking statements” relating to ALR Technologies’ business, and these statements reflect the current views of ALR Technologies with respect to future events and are subject to certain risks, uncertainties and assumptions. When used, the words “estimate”, “expect”, “anticipate”, “believe” and similar expressions are intended to identify such forward-looking statements. There are many factors that could cause the actual results, performance or achievements of ALR Technologies and its products to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Further management discussions of risks and uncertainties can be found in the company’s quarterly filings with the Securities Exchange Commission.

Public Relations:
ALR Technologies Inc.
804-554-3500 Ext. 704
e-mail: [email protected]

ALR Technologies (ALRT) Stock Quote and News:

Disclaimer: Neither nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated three thousand dollars for one month of consultation and journalism services and to manage an investor relations/awareness program by ALR Technologies. Viper has completed prior service agreements with ALRT Technologies with full disclosure listed on our disclaimer/disclosure page. Please read and fully understand our entire disclaimer at


Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Cardium Therapeutics Boosts Energy Supplement Sales

Cardium Therapeutics Boosts Energy Supplement Sales(0)

A recent article on San Diego Biotechnology Connection: Cardium boosts energy supplement sales with national marketing muscle Cardium Therapeutics’ purchase of To Go Brands and its nationwide marketing network is expected to boost energy supplement sales of Cardium’s MedPodium line, including Neo-Chill, which promotes relaxation without drowsiness and contains Suntheanine, a patented, proprietary L-theanine (an

Stocks Gallop Home with Earnings in Focus

Stocks Gallop Home with Earnings in Focus(0)

Stocks moved higher Monday as investors welcomed a sharp rise in retail sales and better-than-expected quarterly earnings from Citigroup. The Dow Jones Industrial average leaped 95.38 points to close at 13,424.20 The S&P 500 prospered 11.54 points to 1,440.13, while the tech-rich Nasdaq recovered 20.07 points to 3,064.18 Bank stocks were among the best performers

Intellect Neurosciences Sues Pfizer Over $2 Million Milestone Payment

Intellect Neurosciences Sues Pfizer Over $2 Million Milestone Payment(0)

Intellect Neurosciences (OTCQB: ILNS), a junior biotech conducting research regarding proprietary drug candidates to treat Alzheimer’s disease (AD) and other diseases associated with oxidative stress, said this morning that it has filed a lawsuit in the New York State Supreme Court against a top tier global pharmaceutical company for breach of the licensing agreement between

Nautilus Stock Chart Analysis Video

Nautilus Stock Chart Analysis Video(0)

Although the chart for Nautilus Inc. (NYSE: NLS) fell sharply in July, the stock has still posted solid gains for 2012 and is back on the rise. Resistance is ahead around $3.00, but the chart is showing bullish signs of trend and momentum, indicating that if the resistance is broken, a run at the 52-week

Stocks Struggle for a Reason to Move on Tuesday

Stocks Struggle for a Reason to Move on Tuesday(0)

American stocks were mixed with the Dow edging lower and the S&P 500 and Nasdaq squeaking ahead on Tuesday as a lack of conviction kept investors on the sidelines. Sentiment is torn ahead of quarterly reports starting to flow in and the euro zone’s financial turmoil as Spain is in focus in need of a

read more

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.